Effect of Apatinib Combined with Tizio on Clinical Efficacy and Serum VEGF and ESM-1 in Patients with Advanced Gastric Cancer

Abstract

Abstract: Objective To explore the clinical efficacy of Apatinib combined with Tizio in patients with advanced gastric cancer and the effects of serum vascular endothelial growth factor (VEGF) and endothelial cell specific molecule-1 (ESM-1). Methods The clinical data of 50 patients with advanced gastric cancer admitted to our hospital from January 2017 to June 2022 were retrospectively analyzed, and they were divided into control group (25 cases) and study group (25 cases) according to different chemotherapy regimen. The control group was treated with Tiggio, and the study group was treated with Apatinib combined with Tiggio for two courses. The clinical efficacy of the two groups was observed, and the levels of serum tumor markers [regenerative gene protein Ⅳ (REGⅣ), response factor (SRF) and matrix metalloproteinase-2 (MMP-2)], VEGF and ESM-1 in the two groups were compared before and after treatment, and safety assessment was carried out. Results The Objective remission rate of the study group was higher than that of the control group, and the difference was statistically significant (P<0.05). After treatment, the serum REG, SRF and MMP-2 levels in two groups were decreased compared with before treatment, and the research group was lower than the control group, the difference was statistically significant (P<0.05). After treatment, the serum VEGF and ESM-1 levels in two groups were decreased compared with before treatment, and the levels in the study group were lower than those in the control group, the difference was statistically significant (P<0.05). There was no significant difference in the incidence of bone marrow transplantation, nausea and vomiting, alopecia, diarrhea and abnormal liver and kidney function between two groups (P>0.05). Conclusion Combined treatment with Apatinib and Tizio has a definite effect in patients with advanced gastric cancer, which can better down-regulate the expression of serum tumor markers, regulate the levels of serum VEGF and ESM-1, and does not increase the incidence of adverse reactions. It is safe and worthy of promotion.

Key words: advanced gastric cancer, Apatinib, Tizio, clinical effect, vascular endothelial growth factor, endothelial cell specific molecule-1

CLC Number:

R735.2

DING Mingcui, MU Ling. Effect of Apatinib Combined with Tizio on Clinical Efficacy and Serum VEGF and ESM-1 in Patients with Advanced Gastric Cancer[J]. ZHONGHUA YANGSHENG BAOJIAN, 2023, 41(17): 15-18.

References

[1] 陈林林,樊慧,王花花,等.沙利度胺联合SOX方案治疗晚期胃癌疗效观察[J].中华实用诊断与治疗杂志,2021,35(11):1134-1139.
[2] 姜志超,张雯,孙永琨,等.FOLFOXIRI改良方案一线治疗晚期胃癌疗效及安全性分析[J].中国肿瘤临床,2020,47(9):438-441.
[3] 刘剑,吉浩明,刘春桂,等.替吉奥联合奥沙利铂对中晚期胃癌的疗效[J].西北药学杂志,2021,36(2):267-270.
[4] 殷国庆,王忠,周峰,等.替吉奥与阿帕替尼单药二线治疗晚期胃癌伴肝转移的效果对比[J].广西医学,2020,42(4):425-428.
[5] 何捷. 阿帕替尼联合化疗治疗晚期胃癌疗效观察[J].中国药物与临床,2020,20(11):1882-1884.
[6] 贾新立,何世威,田秀岭,等.甲磺酸阿帕替尼治疗晚期胃癌的疗效及安全性分析[J].现代肿瘤医学,2021,29(7):1192-1195.
[7] 蔡明志,王学军,刘勇,等.以替吉奥为基础联合阿帕替尼的三药方案在不可切除晚期胃癌转化治疗中的应用[J].中华胃肠外科杂志,2021,25(2):179-184.
[8] 中国临床肿瘤学会指南工作委员会.中国临床肿瘤学会(CSCO)胃癌诊疗指南[M].北京:人民卫生出版社,2018:12,129.
[9] 刘秋华,林榕波.实体瘤疗效评价标准(RECIST)指南1.1版[C].//第十二届全国临床肿瘤大会暨2009年CSCO学术年会论文集. 2009:451-451.
[10] 郭军,王娜,刘登湘,等.甲磺酸阿帕替尼片联合替吉奥和奥沙利铂治疗晚期胃癌的效果与安全性[J].中国医药,2020,15(4):577-579.
[11] 袁海峰. 替吉奥胶囊治疗对胃癌患者血清sICAM-1,Survivin CA199,CA72-4水平的影响[J].检验医学与临床,2020,17(23):3488-3491.
[12] 丁利芳,张惠洁.阿帕替尼联合SOX方案对晚期胃癌患者疗效的影响[J].中国现代应用药学,2022,39(5):653-657.
[13] 刘甫,马沛,魏海.甲磺酸阿帕替尼片治疗晚期胃癌的疗效[J].医学临床研究,2021,38(6):883-885,889.
[14] 王旋,崔立春,党升强.阿帕替尼联合放化疗对晚期胃癌疗效及肿瘤标志物的影响[J].国际肿瘤学杂志,2021,48(10):602-607.
[15] 蔡清,徐金发,章秀芳,等.阿帕替尼联合替吉奥二线治疗Ⅲ-Ⅳ期胃癌近期疗效及对血清CEA和CA19-9水平的影响[J].临床与病理杂志,2020,40(8):1955-1960.